Commercial viability for cell and gene therapy requires the right approach to manufacturing. This webinar, sponsored by Project Farma and Precision ADVANCE addressed public market trends and their impact on the decision to manufacture cell and gene therapies internally or with an external supplier such as a CDMO. Our panel of experts discussed their organizations’ pipeline, the advanced therapy investment landscape, and the regulatory, manufacturing, and commercial requirements for successfully bringing an advanced therapy to market.
Sponsored by Precision ADVANCE, the panel featured insights from industry leaders on their organization’s pipeline, the advanced therapy investment landscape, and the regulatory, manufacturing, and commercial needs to successfully bring an advanced therapy to market. This discussion was moderated by Adam Pfeiffer (VP of Strategy, project Farma), and included insights from Jason Politi (SVP, Technical Operations, Verve Therapeutics), Robert Preti (Strategic Advisor, Ori Biotech), Michael Kuo (SR. VP of Manufacturing, Vita Therapeutics), Tony Khoury (Executive VP, Project Farma), and Ran Zheng (CEO, Landmark Bio).
Key points to be discussed:
- Learn key factors to consider when scaling up a cell or gene therapy facility
- Understand the current state of the public markets and their impact on manufacturing cell and gene therapies
- Make vs. Buy and the advantages and challenges of both solutions